Efficacy of thiopurines and adalimumab in preventing Crohn's disease recurrence in high-risk patients - a POCER study analysis
P De Cruz, MA Kamm, AL Hamilton, KJ Ritchie, EO Krejany, A Gorelik, D Liew, L Prideaux, IC Lawrance, JM Andrews, PA Bampton, S Jakobovits, TH Florin, PR Gibson, H Debinski, RB Gearry, FA Macrae, RW Leong, I Kronborg, G Radford-Smith Show all
Alimentary pharmacology & therapeutics | WILEY | Published : 2015
AbbVie supplied the adalimumab provided in this study, and provided study support, but played no part in study design, analysis or reporting. The Gutsy Group, Gandel Philanthropy, Angior Foundation and Crohns Colitis Australia provided research support. The NHMRC supported PDC and MAK. We are grateful to colleagues and to all centres for their participation.